Side-by-side · Research reference
AOD-9604vsDSIP
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed10/47 cited
BHuman-MechanisticDraft8/36 cited
AOD-9604
HGH 176-191 · β3-AR Lipolytic
SQ · Abdomen · Daily fasted
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
01Mechanism of Action
Parameter
AOD-9604
DSIP
Primary target
β3-adrenergic receptor (proposed)Ng 2008
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
Pathway
β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
Downstream effect
Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Feedback intact?
No GH-axis or IGF-1 feedback
—
Origin
Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Antibody development
—
—
02Dosage Protocols
Parameter
AOD-9604
DSIP
Standard dose
250–300 mcg / dayHeffernan 2001
Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.
100–200 mcg SQ pre-sleepSchneider 1986
Frequency
Once daily, fasted
Once daily, pre-sleep
Lower / starter dose
150 mcg / day
50 mcg pre-sleep
Evidence basis
Phase 2 trials + animal-strongHeffernan 2001Ng 2008
Human-mechanistic + early clinicalSchneider 1986
Duration
8–12 weeks per cycle
8–12 weeks per cycle
Reconstitution
Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL
Bacteriostatic water
Timing
Morning fasted preferred (pre-cardio)
Aligns with circadian lipolysis.
30–60 min pre-sleep
Half-life
~30 min plasma
Short plasma; CNS effects last hours
04Side Effects & Safety
Parameter
AOD-9604
DSIP
Injection site reaction
Mild erythema
Mild irritation
GI symptoms
Rare mild nausea
—
Cardiovascular
Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)
—
Cancer risk
No GH/IGF-1 axis activity → lower theoretical risk vs HGH
—
Pregnancy / OB
Avoid
Avoid
Drowsiness
—
Expected effect (intentional)
Vivid dreams
—
Anecdotally reported
Long-term safety
—
Limited modern RCT data
Absolute Contraindications
AOD-9604
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease (caution with β-receptor agonists)
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
Relative Contraindications
AOD-9604
- ·Concurrent β-blocker therapy (theoretical antagonism)
- ·Pheochromocytoma
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
05Administration Protocol
Parameter
AOD-9604
DSIP
1. Reconstitution
Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.
Add 1–2 mL bacteriostatic water to vial.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ — abdomen. Rotate sites.
3. Timing
Morning, fasted, ideally pre-cardio for amplified fat oxidation.
30–60 min pre-sleep.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G insulin syringe.
06Stack Synergy
AOD-9604
+ MOTS-c
ModerateAOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.
- AOD-9604
- 250–300 mcg SQ · morning fasted (daily)
- MOTS-c
- 5 mg SQ · 2–3× per week (pre-workout)
- Primary benefit
- Fat mobilisation + mitochondrial oxidation, no IGF-1 concern
DSIP
— no documented stacks